Zenas BioPharma outlines Monarch Phase 3 trial design for orelabrutinib in non-active secondary progressive MS
Bitget2026/10/07 11:05Zenas BioPharma flagged seven posters for MSToronto2026 on Oct. 21-23, 2026, outlining orelabrutinib and obexelimab clinical updates. New results will be presented at the meeting, including 24-week findings from a Phase 2 relapsing-remitting multiple sclerosis study of orelabrutinib. Another set of posters will preview Phase 3 trial designs testing orelabrutinib in non-active secondary progressive multiple sclerosis and primary progressive multiple sclerosis. Separate MoonStone Phase 2 posters will present obexelimab data indicating reduced disease activity, supported by biomarker and exposure-response analyses. A company symposium will frame BTK inhibition as a potential approach to slowing disability progression in progressive multiple sclerosis. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070705PRIMZONEFULLFEED9841312) on October 07, 2026, and is solely responsible for the information contained therein.
- Zenas BioPharma flagged seven posters for MSToronto2026 on Oct. 21-23, 2026, outlining orelabrutinib and obexelimab clinical updates.
- New results will be presented at the meeting, including 24-week findings from a Phase 2 relapsing-remitting multiple sclerosis study of orelabrutinib.
- Another set of posters will preview Phase 3 trial designs testing orelabrutinib in non-active secondary progressive multiple sclerosis and primary progressive multiple sclerosis.
- Separate MoonStone Phase 2 posters will present obexelimab data indicating reduced disease activity, supported by biomarker and exposure-response analyses.
- A company symposium will frame BTK inhibition as a potential approach to slowing disability progression in progressive multiple sclerosis.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Crypto prices
More
